Breast cancer (1)
B33 – B67
- B33: Time to full publication of studies of anti-cancer drug for breast cancer, and the potential for publication bias
- B34: Projecting the impact on breast cancer mortality of increasing the upper age limit for breast screening
- B35: The feasibility of long term Quality of Life (QoL) studies to identify breast cancer survivorship issues – the TACT trial experience
- B36: Follow-up care for breast cancer survivors: the views of breast cancer experts
- B37: Prevalent cases in observational epidemiological studies of cancer survival: do they bias hazard ratio estimates?
- B38: 'Cure' from breast cancer amongst two populations of women followed for twenty-three years after diagnosis
- B39: No association between MGMT codon 143 polymorphism and risk of breast, colorectal and prostate cancers in EPIC-Norfolk Study
- B40: Identification of Human papillomavirus DNA sequences in female breast carcinomas in Japan
- B41: Role of established hormonal and reproductive risk factors in breast cancer: do they apply in Pakistan?
- B42: CYP2D6 variants and their association with breast cancer susceptibility
- B43: Impaired tamoxifen metabolism reduces survival in familial breast cancer patients
- B44: A novel role for CtBP proteins in the regulation of mitotic fidelity in breast cancer cells
- B45: The recruitment of insulin receptor substrate 1 (IRS-1) by erbB3 in oestrogen receptor (ER)-positive breast cancer cell lines
- B46: From association to causative variant – fine-scale mapping of breast cancer susceptibility loci identified from Genome Wide Association Scans (GWAS)
- B47: Pharmacogenomic profiling of the PI3K/PTEN pathway in sporadic breast cancer
- B48: Differential regulation of CYP4Z1 mRNA in human breast cancer cell lines
- B49: A high-throughput method for measuring mean telomere length and its application to cancer susceptibility studies
- B50: Illumina gene expression profiling in taxane resistant breast cancer cell lines
- B51: Non-invasive imaging of ER: coregulator interactions using luciferase fragment complementation
- B52: The role of macrophages in tumour revascularisation following combretastatin A-4-phosphate (CA-4-P) treatment
- B53: The transcriptional coactivator p68 regulates expression of novel p53 isoforms that are critical for transcriptional activation by p53
- B54: Cancer stem cells are not more radioresistant than non-stem cells in cell lines from different origins with the exception of the MDA MB231 breast cancer cell line
- B55: Modelling estrogen receptor alpha-positive breast cancer by transformation of normal human mammary epithelial cells
- B56: Genome-wide SNP–LOH analysis of early ipsilateral breast cancer recurrences in women under 50 years of age
- B57: Metastasis suppressor 1 (MTSS1) demonstrates prognostic and anti-metastatic potential in human breast cancer
- B58: The aberrant expression of Bone Morphogenetic Protein 12 (BMP12) in human breast cancer and its potential prognostic value
- B59: The role of KAI-1 in the adhesive, growth and invasive capacity of breast cancer cell lines
- B60: Histopathological characterisation of lymph vessels in breast cancer and their role in disease progression
- B61: Inhibition of Src kinase restores cell-cell adhesion and suppresses the aggressive phenotype of endocrine-resistant breast cancer cells
- B62: Metastasis to bone in human breast cancer is associated with loss of Occludin expression
- B63: Mutations in the MMAC1 gene in Iranian patients that are Associated with Cowden Disease and Juvenile Polyposis syndrome
- B64: Rates of neutropaenic sepsis with the use of adjuvant FEC100-Docetaxel (FEC100-T) chemotherapy in high-risk node-positive patients with early breast cancer; A UK perspective
- B65: Assessment of clinical and pathological response of locally advanced breast cancer to neoadjuvant docetaxel, epirubicin and cyclophosphamide
- B66: Integration of HER-2 result into breast multi-disciplinary decision making: results of a UK audit
- B67: Experience of febrile neutropaenia and secondary G-CSF prophylaxis during FEC-D chemotherapy in Merseyside and Cheshire Cancer Network
